MOUD Buprenorphine Sublocade denied as experimental or investigational by Express Scripts?

Sublocade requires 7+ days sublingual buprenorphine stabilization before LA injectable approved.

Patient-specific justification: prior buprenorphine non-adherence, diversion concerns, work/travel adherence challenges, prior overdose, pregnancy. ASAM NPG OUD 2020. Cite HOFER pivotal (Haight 2019, Lancet). MHPAEA 2024 Final Rule NQTL — demand comparative analysis.

## Why Express Scripts Labels Sublocade "Experimental" — and Why That Is Wrong

Express Scripts or the health plans it serves sometimes deny Sublocade (buprenorphine extended-release subcutaneous injection) on grounds that it is "experimental," "investigational," or "not proven medically necessary" — language that can be triggered by automated utilization management rules that have not been updated to reflect Sublocade's regulatory and clinical history.

This characterization is factually incorrect. Sublocade received FDA approval for moderate-to-severe opioid use disorder in adults following a full regulatory review including clinical trials reviewed by the FDA. It is listed in SAMHSA's treatment guidance and is referenced in ASAM's clinical practice guidelines. An "experimental" denial for an FDA-approved product with established clinical use is one of the most defensible appeal scenarios.

## Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You have 180 days from the denial notice to file an internal appeal. The plan must respond within 30 days (pre-service) or 60 days (post-service).
• Expedited review: Available within 72 hours for urgent clinical situations.
• External independent review (ACA §2719): "Experimental" denials are specifically listed as eligible for external review under federal law — you do not need to exhaust multiple internal levels before requesting external review in most states. You have approximately four months from the denial to initiate this.
• MHPAEA: If experimental denials are applied to substance use disorder treatment more broadly than to analogous medical conditions, a parity challenge is available.

## The Appeal Process

1. Obtain the denial letter and confirm the specific "experimental/investigational" definition the plan is applying. 2. Gather evidence that Sublocade does not meet that definition: it holds full FDA approval, is listed in peer-reviewed clinical guidelines, and is covered by CMS for Medicare beneficiaries. 3. File a written internal appeal with the documentation below. 4. Simultaneously (or immediately after internal denial) request external independent review — external reviewers reverse experimental denials for FDA-approved drugs at high rates.

## Documentation to Gather

• FDA approval documentation: A reference to Sublocade's FDA approval letter and approved labeling (publicly available on FDA.gov) confirming this is not an investigational product.
• Guideline citations: Generic reference to SAMHSA MOUD treatment improvement protocols and ASAM clinical practice guidelines that include extended-release injectable buprenorphine as a recommended treatment option.
• Clinical necessity letter: Prescriber letter documenting the patient's diagnosis, treatment history, and why the injectable extended-release formulation is the appropriate choice for this individual.
• Diagnosis and severity documentation: DSM-5 OUD diagnosis, severity specifier, comorbidities, and any history of overdose, relapse, or treatment engagement challenges.
• Medicare/Medicaid coverage reference: If applicable, note that federal programs cover Sublocade — this directly undercuts an "experimental" characterization.

## Criteria-Mapping Structure

| Plan "Experimental" Criterion | Your Rebuttal Evidence | |---|---| | Not FDA-approved | FDA-approved; cite FDA.gov approval date | | Insufficient clinical evidence | ASAM + SAMHSA guidelines; federal program coverage | | Not standard of care | Included in national MOUD treatment protocols | | Individual medical necessity | Prescriber letter with chart documentation |